Every DEF 14A that bioAffinity Technologies, Inc. (BIAF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BIAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAF filings page.
bioAffinity Technologies, Inc. (BIAF) is asking stockholders at its November 20, 2026 special meeting to approve five proposals. Two would permit the issuance of up to 1,128,272 shares under August warrants and up to 980,072 shares under October warrants, each only after stockholder approval. The company estimates potential gross proceeds of up to approximately $5.6 million from the August warrants and $6.0 million from the October warrants if all are exercised for cash at their applicable exercise prices.
A separate proposal would authorize one or more non-public offerings of up to 10,000,000 shares and $15,000,000 in aggregate cash consideration, at discounts up to 20% below market, on or before November 20, 2027. Another proposal would reduce authorized common shares from 350,000,000 to 200,000,000; if approved, the Board may implement or abandon the change at its discretion. The Board recommends voting FOR all five proposals.
bioAffinity Technologies is asking stockholders at its April 30, 2026 annual meeting to approve a broad set of governance and financing proposals. These include electing six directors and ratifying WithumSmith+Brown, PC as auditor for the year ending December 31, 2026.
The proxy also seeks approval for issuing up to 271,500 shares upon exercise of August 2025 warrants and related anti-dilution adjustments that could increase warrant and Series B preferred share issuances. The Board requests authorization for non‑public offerings, potential change of control under Nasdaq rules, a 1‑for‑2 to 1‑for‑250 reverse stock split at the Board’s discretion, and an adjournment option.
In addition, the company proposes amending its 2024 Equity Incentive Plan to raise the share reserve from 66,666 to 1,000,000 shares, citing the need to attract and retain key employees and directors while aligning compensation with stockholder interests.
bioAffinity Technologies (BIAF) called a Special Meeting to approve multiple share-related actions. The Board asks stockholders to approve: issuing up to 271,500 shares upon exercise of August 2025 warrants; a warrant anti-dilution reset that could raise the exercisable amount up to 365,620 shares; and a Series B Preferred anti-dilution reset allowing up to 131,884 additional conversion shares. The Board also seeks to amend the 2024 Equity Incentive Plan to 750,000 shares from 66,666; authorize one or more non-public offerings of up to 10 million shares for up to $10,000,000 (at discounts up to 35%) through December 31, 2026; approve any Nasdaq Rule 5635 change of control arising from such offerings; and permit adjournment if needed.
As context, shares outstanding were 3,633,815 as of November 4, 2025. The company states the August 2025 warrants, if exercised for cash, could provide up to approximately $2.9 million in gross proceeds. The Board recommends “FOR” on all proposals.